BMC Cancer

CORRECTION

Open Access

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥1 line of endocrine therapy: systematic review and meta-analysis

Xiewei Huang[1,3†], Yushuai Yu[1,3†], Shiping Luo[1,3], Wenfen Fu[1,3], Jie Zhang[1,2,3*] and Chuangui Song[1,2,3*]

Correction: BMC Cancer 24, 21 (2024)
https://doi.org/10.1186/s12885-023-11722-4

Following publication of the original article [1], the authors reported an error in the fourth sentence of the first paragraph of the "Safety" sub-section of the "Results" section (copied and in bold below for your ease of reference): **The proportion of drug discontinuation caused by TEAEs in the three treatment groups of SERENA-2 was 14.9% (camizestrant 75 mg), 21.9% (camizestrant 150 mg), and 4.1% (standard-of-care ET), respectively.**

We have quoted the proportion of TEAEs leading to dose interruption, rather than those leading to discontinuation which is an error. The correct sentence should be: **The proportion of drug discontinuation caused by treatment related AEs (TRAEs) in the three treatment groups of SERENA-2 was 2.7% (camizestrant 75 mg), 0% (camizestrant 150 mg), and 0% (fulvestrant as standard-of-care ET), respectively.**

The original article [1] has been corrected.

Published online: 13 February 2024

†Xiewei Huang and Yushuai Yu contributed equally to this work and share first authorship.

The online version of the original article can be found at https://doi.org/10.1186/s12885-023-11722-4.

*Correspondence:
Jie Zhang
zjie1979@gmail.com
Chuangui Song
Songcg1971@hotmail.com
[1]Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001 Fuzhou, Fujian Province, China
[2]Department of General Surgery, Fujian Medical University Union Hospital, 350001 Fuzhou, Fujian Province, China
[3]Breast Surgery Institute, Fujian Medical University, 350001 Fuzhou, Fujian Province, China

References

1. Huang X, Yu Y, Luo S, et al. The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer. 2024;24:21. https://doi.org/10.1186/s12885-023-11722-4.

Publisher's Note